粉样β的作用的多样性
Sona Mardanyan1, Svetlana Sharoyan1, Alvard Antonyan1
1H. Buniatian Institute of Biochemistry of Armenian National Academy of Sciences, Yerevan 0014, Republic of Armenia.
Reviews in the neurosciences
|January 28, 2024
概括
胺β (Aβs) 可能具有有益的作用,其病理效应与其他疾病有关. 植物制剂维持了Aβs的生理状态,这表明阿尔茨海默病 (AD) 的新治疗点.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 氨基原蛋白,如氨基β (Aβs),与不可治愈的疾病有关,特别是阿尔茨海默病 (AD).
- 目前的AD研究主要集中在减少Aβs以防止聚合和神经退行.
- 新出现的证据表明,Aβs可能具有生理功能,病理影响可能来自其他疾病状态.
研究的目的:
- 审查Aβs在健康和疾病中的双重作用.
- 探索促进聚合的Aβs的酶性修饰.
- 研究植物化合物在控制Aβs.中的潜力.
主要方法:
- 关于粉样蛋白生成和阿尔茨海默病的研究的文献综述.
- 在Aβ修饰中,分析涉及谷氨基基酶和二乙基酸酶IV的酶途径.
- 对植物制剂对Aβs的影响的实验数据的评估.
主要成果:
- Aβs表现出生理功能,其病理影响可能取决于疾病背景.
- 酶的修改 (例如,由谷氨基酸环酶) 增强了Aβ聚合.
- 植物制剂在维持Aβs的生理,非聚合状态方面表现出有效性.
结论:
- 建议在AD治疗中将重点从Aβs去除转移到治疗潜在疾病.
- 谷氨基胺基环酸酶和二基酸酶IV是阿尔茨海默病的潜在治疗点.
- 黄类药物和植物制剂显示出作为神经保护剂,抗癌剂和抗糖尿病剂的前景.
相关概念视频
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
Alzheimer's Disease: Treatment
193
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
193
Alzheimer's Disease: Overview
487
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
487


